A 45-Year-Old Using Donor Eggs Has Better IVF Odds Than a 38-Year-Old Using Her Own: What the Success Rate Data Shows
The Number That Should Change How You Think About IVF
A woman who is 45 or older, using donor eggs, had a 48.5% live birth rate per transfer in 2019. A woman aged 38 to 40, using her own frozen eggs, had a 32.7% live birth rate in 2021.
Read that again. The older patient had a 15.8-percentage-point advantage over the younger one. The variable that explains most of that gap is not uterine function, not clinic quality, not protocol design. It is whose eggs were used.
This is not a subtle finding buried in a footnote. It is visible in the national aggregate data, which means it is almost certainly larger in the highest-performing clinics and smaller in the lowest-performing ones. Yet most fertility patients enter their first consultation thinking about their age as the primary risk factor, because that is how clinics frame the conversation. The data suggests the more precise framing is: the age of the egg, not the age of the patient, is the dominant variable in IVF outcomes.
That reframing has real financial consequences. Donor egg cycles cost more upfront. But if the success rate differential is large enough, the cost-per-live-birth calculation can invert entirely. Understanding that math before you choose a protocol is not a luxury. For patients in the 38-to-45 age range, it may be the most important number in the entire decision.
What the Live Birth Rate Data Actually Shows
The CDC publishes annual ART success rates by clinic, age group, and cycle type. Parsing those tables reveals a pattern that national fertility discourse tends to flatten.
For women aged 35 to 37, using fresh non-donor eggs in 2023, the national live birth rate was 38.4% per transfer. That is a reasonable result for a patient in her mid-to-late thirties using her own genetic material through a fresh retrieval cycle.
Now consider what happens when you shift the egg source rather than the patient age. Women aged 38 to 40 using donor eggs in 2020 had a 50.5% live birth rate. The patients are older. The success rate is higher by 12.1 percentage points. The only thing that changed is the origin of the egg.
The 2019 donor egg data for the same 38-to-40 cohort shows 50.0%, confirming this is not a single-year anomaly. Donor egg success rates in this age band have been persistently hovering around 50%, year over year, while own-egg frozen cycles for the same patients land in the low thirties.
The 17.8-point gap between frozen non-donor (32.7%) and donor (50.5%) for women aged 38 to 40 is the number that should anchor every consultation a patient in that age range has with a reproductive endocrinologist.
Why Egg Age Matters More Than Patient Age
Human eggs are subject to chromosomal degradation over time. Aneuploidy rates, the rate at which embryos carry chromosomal errors that prevent implantation or cause miscarriage, rise sharply after 35 and accelerate past 38. This is not a function of ovarian reserve declining. It is a function of cumulative oxidative stress and spindle apparatus deterioration in the oocyte itself.
The uterus ages too, but far more slowly and in ways that are often addressable through hormonal support. A 45-year-old uterus, properly prepared, can carry a chromosomally normal embryo to term at rates that are surprisingly close to those of a woman in her late thirties. The 2019 data makes this concrete: women 45 and older using donor eggs achieved a 48.5% live birth rate. That is within two percentage points of the donor egg rate for women aged 38 to 40.
What this means practically is that the uterus is not the bottleneck for most patients who fail IVF in their late thirties and forties. The egg is. Clinics that lead with "your age is the issue" are not technically wrong, but they are describing a proxy variable when the mechanism is more specific.
Preimplantation genetic testing for aneuploidy (PGT-A) exists precisely to compensate for this problem with own eggs. A euploid embryo from a 40-year-old patient, once selected, has a transfer success rate that is meaningfully higher than an untested embryo from the same cohort. But PGT-A requires embryos to test, and that requires successful retrievals, and the retrieval rate itself is a function of egg quality. The donor egg approach sidesteps this cascade entirely by starting with younger genetic material.
The Cost Math That Clinics Rarely Show You
A donor egg cycle in the United States typically costs between $25,000 and $45,000 depending on whether you use a fresh or frozen donor, what agency you use, and what clinic performs the transfer. That is two to three times the cost of a standard own-egg IVF cycle.
The instinctive reaction is that donor eggs are unaffordable. But that framing ignores the denominator.
If a 39-year-old woman has a 32.7% live birth rate per frozen non-donor transfer, she needs roughly 3.1 transfers on average to achieve a live birth, assuming each transfer is independent (a simplification, but a reasonable one for back-of-envelope purposes). At $15,000 per cycle, that is approximately $46,500 in transfer costs before accounting for retrieval, medications, and monitoring, which easily push the total past $70,000 to $90,000 for multiple complete cycles.
If the same patient switches to donor eggs at a 50.5% live birth rate, she needs roughly 2 transfers on average. At $30,000 per donor cycle, that is $60,000, and the cycle often includes the retrieval step within the bundled cost.
The expected cost-per-live-birth can actually be lower with donor eggs despite the higher per-cycle price. This is not guaranteed, and the math shifts depending on specific clinic success rates, how many own-egg retrievals a patient would need to bank embryos, and whether insurance covers any portion of either protocol. But the calculation is worth running before you default to "own eggs first because they're cheaper."
Explore the data for your specific age group and compare protocol outcomes at Feralyx to see how the cost-per-live-birth math works at different success rate assumptions.
The 35-to-37 Window Is Where the Calculus Shifts
The fresh non-donor data for women aged 35 to 37 complicates the picture in a useful way. The 38.4% live birth rate for this cohort is lower than the donor egg rate for the 38-to-40 cohort by more than 12 percentage points. But it is also lower than what many patients and their partners assume going into treatment.
A 36-year-old using fresh own eggs is not necessarily in a strong position. She is in a better position than she would be at 39, but the absolute success rate per transfer still means she has a better-than-60% chance of a given transfer not resulting in a live birth. Compounding that across multiple cycles is what drives the emotional and financial attrition that characterizes the fertility treatment experience for so many families.
The relevant question for a 35-to-37 patient is not just "are my odds decent?" but "how many transfers am I likely to need, and what is my reserve of retrievable eggs?" A patient who retrieves two eggs per cycle and gets one blastocyst that fails to implant is in a different position than a patient who retrieves 12 eggs and banks four euploid embryos. Age predicts average outcomes. The distribution within that age band is wide enough that per-patient data matters more than cohort averages.
This is where clinic selection becomes a confounding factor that national averages cannot capture. A clinic reporting 38.4% for the 35-to-37 fresh non-donor cohort is at or near the national mean. But the range across clinics for this cohort spans from under 25% to over 55%. The patient who walks into a clinic near the bottom of that distribution and the patient who walks into one near the top are not having the same experience, even if they are the same age with the same diagnosis.
What to Do With This Information Before Your Next Consultation
The insight from this data is not that you should immediately pursue donor eggs. For many patients, own-egg IVF is the right protocol, for genetic connection reasons, for cost reasons, or because the clinical picture suggests adequate egg quality. The insight is that the decision between protocols deserves quantitative framing, not just a clinician's intuition or a general recommendation based on age.
Three questions worth bringing to your next reproductive endocrinology appointment:
The first is what your clinic's specific live birth rate is for your age group and cycle type, not the national average. Clinics are required to report this data to SART and the CDC. If the number is not readily available to you, that itself is information about how the clinic operates.
The second is what your antral follicle count and AMH level suggest about expected egg yield per retrieval. The national average success rate for frozen non-donor cycles assumes a certain distribution of egg quality and quantity. If your ovarian reserve markers put you in the bottom quartile of your age cohort, the national average overstates your expected outcome.
The third is what a donor egg scenario would cost at that clinic, and whether your insurance mandate, if you have one, covers any part of a donor cycle. State mandates vary significantly in what they require, and some cover donor egg cycles while others do not. The presence or absence of that coverage can shift the cost-per-live-birth calculation materially.
The broader point is that fertility treatment is one of the few major medical decisions where patients are routinely asked to make five-figure financial commitments based on population averages rather than individual probability estimates. The data exists to do better than that. The 17.8-point gap between donor and non-donor outcomes for women aged 38 to 40 is not a secret. It is just not the number most consultations lead with.
It should be.
Related Analysis
Other Smart Technology Investments tools that bear on this decision: